Re-immunotherapy with Nivolumab plus Ipilimumab in Advanced NSCLC Patients Previously Treated with Anti-PD-(L)1 Antibody-MedSci.cn

Re-immunotherapy with Nivolumab plus Ipilimumab in Advanced NSCLC Patients Previously Treated with Anti-PD-(L)1 Antibody

Imakita, T; Fujita, K; Ito, T; Saito, Z; Oi, I; Kanai, O; Tachibana, H; Mio, T

JOURNAL OF THORACIC ONCOLOGY, 2023; 18 (11): S627

科室
- - 订阅+
  - 更多科室
工具
服务